Clinical Trials Logo

Filter by:
NCT ID: NCT05396729 Recruiting - Sleep Disorder Clinical Trials

Acupoint Stimulation Improves Sleep on the Plateau

ASSOP
Start date: July 30, 2022
Phase: N/A
Study type: Interventional

Sleep disorder is common in people going to plateau. Acupuncture and related techniques could be used for treatment of sleep disorder. In this trial the effect of transcutaneous electrical acupoint stimulation on sleep disorder in people going to plateau will be investigated.

NCT ID: NCT05396391 Recruiting - Clinical trials for Advanced Malignant Tumors

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Start date: June 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

NCT ID: NCT05396339 Recruiting - Clinical trials for Advanced Malignant Solid Tumor

A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.

Start date: June 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.

NCT ID: NCT05396313 Recruiting - Clinical trials for Sudden Cardiac Death

Prediction of Mortality After CIED Implantation (PM-CIED)

PM-CIED
Start date: August 2004
Phase:
Study type: Observational

The study aims to develop and validate predictive models for the mortality of patients receiving CIED (including CRT and ICD) implantation.

NCT ID: NCT05396300 Recruiting - Colorectal Cancer Clinical Trials

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Start date: May 25, 2022
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05396209 Recruiting - Macular Holes Clinical Trials

To Evaluate the Therapeutic Efficacy of Hydrated Amniotic Membrane in Promoting Closure of Refractory Macular Holes.

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To compare anatomic and functional results, and to evaluate postoperatively the healing process in 3 different techniques for the closure of the refractory macular holes (MH).

NCT ID: NCT05396183 Recruiting - Clinical trials for Head and Neck Neoplasms

Accuracy and Safety of Coplanar Template Assistance for Head and Neck Biopsies.

Start date: May 25, 2022
Phase:
Study type: Observational

This is a prospective single-arm cohort study to evaluate the accuracy and safety of three-dimensional printing co-planer template(3D-PCT) for computed tomography (CT)-guided neck and head biopsy .

NCT ID: NCT05395780 Recruiting - Gastric Cancer Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Start date: June 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.

NCT ID: NCT05395533 Recruiting - Clinical trials for CD20-positive B-cell Non-Hodgkin Lymphoma

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Start date: September 8, 2020
Phase: Phase 1
Study type: Interventional

This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.

NCT ID: NCT05395507 Recruiting - Clinical trials for Essential Thrombocytopenia

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

Objectives: To compare the efficacy and safety in Adult patients (≥18 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study Design: A prospective, open-label, multicenter, randomized controlled clinical trial.